- Trials with a EudraCT protocol (1,699)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (11)
1,699 result(s) found for: Point of care.
Displaying page 5 of 85.
EudraCT Number: 2010-024552-28 | Sponsor Protocol Number: 1 | Start Date*: 2012-12-03 |
Sponsor Name:Oxford Radcliffe Hospitals NHS Trust | ||
Full Title: BRUISE CONTROL : BRidge or continUe coumadIn for device SurgEry randomized CONTROLled Trial | ||
Medical condition: The primary study endpoint is the risk of haematoma formation with cardiac device operation using either warfarin anticoagulation or heparin | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-002339-23 | Sponsor Protocol Number: MydriasisbeiMydrane | Start Date*: 2019-10-24 |
Sponsor Name:Medical University Graz, Department of Ophtalmology | ||
Full Title: Prospective intraindividual comparison of the mydriasis of a standardized intracameral anaesthetics with the topical preoperative drop application in the uncomplicated cataract surgery | ||
Medical condition: patients who need a cataract surgery in both eyes | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-002343-99 | Sponsor Protocol Number: 1.0 | Start Date*: 2012-01-03 |
Sponsor Name:Heart of England NHS Foundation Trust | ||
Full Title: An Open-label Study into the Efficacy and Dosing of Probiotic Escherichia coli Nissle 1917 for Prevention of Gram-negative Gastric Colonisation in Ventilated Intensive Care Patients. | ||
Medical condition: Gastric colonisation by pathogenic gram negative bacteria in ventilated adult ICU patients and it's prevention by the probiotic E.coli Nissle 1917 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-002471-18 | Sponsor Protocol Number: | Start Date*: 2019-01-18 | |||||||||||
Sponsor Name:Imperial College London | |||||||||||||
Full Title: The clinical effectiveness and cost effectiveness of clozapine for inpatients with borderline personality disorder: randomised controlled trial | |||||||||||||
Medical condition: Borderline Personality Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000429-17 | Sponsor Protocol Number: 00 | Start Date*: 2021-05-20 |
Sponsor Name:University of Oslo, Faculty of Medicine, Institute of Health and Society | ||
Full Title: BASIC - Better treatment for acute sinusitis in primary care: a randomized controlled trial testing topical treatment with chloramphenicol eye drops | ||
Medical condition: Acute rhinosinusitis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NO (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000516-37 | Sponsor Protocol Number: TS-020DESE | Start Date*: 2021-03-04 | |||||||||||
Sponsor Name:TurnSole Biologics Llc | |||||||||||||
Full Title: A Phase I/II open-label study for Azacitidine, initiated with a lead-in dose escalation pharmacokinetic Phase I/b part in the 20–50 mg/m2 range to evaluate safety in Hospitalized COVID-19 Patients ... | |||||||||||||
Medical condition: COVID-19 patients with confirmed sever viral infection of SARS-COV-2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002174-43 | Sponsor Protocol Number: A-48-52030-269 | Start Date*: 2014-03-27 | |||||||||||
Sponsor Name:IPSEN NV | |||||||||||||
Full Title: AN INTERNATIONAL, MULTICENTRIC, PROSPECTIVE, OPEN LABEL STUDY TO ASSESS THE EFFICACY AND SAFETY OF LANREOTIDE AUTOGEL 120 MG ASSOCIATED TO STANDARD OF CARE IN THE TREATMENT OF CLINICAL SYMPTOMS AS... | |||||||||||||
Medical condition: Inoperable malignant intestinal obstruction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001303-36 | Sponsor Protocol Number: TRCA-303 | Start Date*: 2018-11-07 | |||||||||||
Sponsor Name:Tricida Inc. | |||||||||||||
Full Title: A Phase 3b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of TRC101 in Delaying Chronic Kidney Disease Progression in Subjects with Metabolic Acidosis | |||||||||||||
Medical condition: Chronic kidney disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) BG (Prematurely Ended) GB (GB - no longer in EU/EEA) FR (Completed) SK (Completed) CZ (Completed) BE (Completed) ES (Prematurely Ended) PT (Completed) NL (Prematurely Ended) PL (Completed) IT (Prematurely Ended) RO (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001420-34 | Sponsor Protocol Number: 0001 | Start Date*: 2020-04-14 | |||||||||||
Sponsor Name:Aarhus University | |||||||||||||
Full Title: Senicapoc in COVID-19 Patients with Severe Respiratory Insufficiency – A Randomized, Open-Label, Phase II Trial | |||||||||||||
Medical condition: Infection with COVID19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002072-26 | Sponsor Protocol Number: P150939 | Start Date*: 2016-08-25 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Multicenter randomized placebo controlled trial assessing the efficacy of oral adjuvant magnesium supplementation in the treatment of alcohol withdrawal syndrome. | |||||||||||||
Medical condition: Patients experiencing an alcohol withdrawal syndrome. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003105-25 | Sponsor Protocol Number: MiLe-1 | Start Date*: 2014-08-27 |
Sponsor Name:Sahlgrenska University Hospital / The Queen Silvia Children´s Hospital | ||
Full Title: The prophylactic effect of levosimendan in reducing acute kidney injury postoperatively in pediatric patients undergoing corrective heart surgery | ||
Medical condition: Acute kidney injury postoperatively in connection with surgery for congenital heart disease | ||
Disease: | ||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: SE (Completed) FI (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-002154-36 | Sponsor Protocol Number: CIGE025F1301 | Start Date*: 2019-02-13 | ||||||||||||||||
Sponsor Name:Novartis Pharma KK | ||||||||||||||||||
Full Title: A 12 Week, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Omalizumab in Adult and Adolescent Patients With Inadequately Controlled... | ||||||||||||||||||
Medical condition: Severe Japanese cedar pollinosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-005513-18 | Sponsor Protocol Number: FARM6NJ3TZ | Start Date*: 2007-10-04 | |||||||||||
Sponsor Name:OSPEDALE PEDIATRICO BAMBINO GESU' DI ROMA | |||||||||||||
Full Title: Double blind randomized controlled study on the benefit-risk profile of in the treatment of at term or late preterm newborn infants with severe respiratory disorders and pulmonary hypertension | |||||||||||||
Medical condition: treatment of at term or late preterm newborn infants with severe respiratory disorders and pulmonary hypertension | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003218-42 | Sponsor Protocol Number: RC18_0287 | Start Date*: 2019-01-16 |
Sponsor Name:CHU de Nantes | ||
Full Title: Phase 2 study evaluating MEchanisms of resistance on tumor tissue and Liquid biopsy in patients with EGFR mutated nonpretreated advanced Lung cancer Receiving OSimErtinib until and beyond radiologi... | ||
Medical condition: Locally advanced or metastatic Non-small-cell lung carcinoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-005017-31 | Sponsor Protocol Number: DERN | Start Date*: 2019-01-29 | |||||||||||
Sponsor Name:G.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST | |||||||||||||
Full Title: DENOSUMAB IN EBV RELATED NASOPHARYNGEAL CARCINOMA (NPC) AS A MODEL FOR RANK-MEDIATED IMMUNOLOGIC MODULATION OF VIRUS-RELATED TUMOURS – DERN STUDY | |||||||||||||
Medical condition: advanced or metastatic Nose Pharynx Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001587-30 | Sponsor Protocol Number: 012657 | Start Date*: 2019-07-26 | ||||||||||||||||
Sponsor Name:Queen Mary University London | ||||||||||||||||||
Full Title: AZD1656 in Transplantation with Diabetes tO PromoTe Immune TOleraNce | ||||||||||||||||||
Medical condition: renal transplant AND type 2 diabetes | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-005001-26 | Sponsor Protocol Number: 20-773/M | Start Date*: 2021-12-24 |
Sponsor Name:UMC Utrecht | ||
Full Title: Influencing Progression of Airway Disease in Primary Antibody Deficiency | ||
Medical condition: Primary antibody deficiency: - Unclassified antibody deficiency (unPAD) - IgA deficiency - Specific polysaccharide antibody deficiency (SPAD) - IgG subclass deficiency (IgSD) - Common variable immu... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2022-001363-27 | Sponsor Protocol Number: DAY101-002 | Start Date*: 2023-01-18 | |||||||||||
Sponsor Name:Day One Biopharmaceuticals, Inc. (Day One) | |||||||||||||
Full Title: LOGGIC/FIREFLY-2: A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients with Pediatric Low-Grade Glioma Harboring an Activati... | |||||||||||||
Medical condition: Pediatric low-grade glioma harboring an activating RAF alteration requiring first-line systemic therapy | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) IE (Trial now transitioned) HU (Trial now transitioned) DE (Trial now transitioned) NO (Trial now transitioned) BE (Trial now transitioned) FI (Trial now transitioned) AT (Trial now transitioned) SI (Trial now transitioned) GR (Trial now transitioned) DK (Trial now transitioned) CZ (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-005363-52 | Sponsor Protocol Number: IOCtrial | Start Date*: 2014-09-10 |
Sponsor Name:Department of Neurology, Academic Medical Center | ||
Full Title: Intravenous immunoglobulin overtreatment in chronic inflammatory demyelinating polyneuropathy (CIDP) | ||
Medical condition: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-002028-26 | Sponsor Protocol Number: AK0529-1003 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Ark Biosciences Pty Ltd. | |||||||||||||
Full Title: A Randomised, Double-blind, Placebo-controlled, 2-Part Study of Orally Administered AK0529 to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Effect of Single and Multiple Dosing ... | |||||||||||||
Medical condition: Respiratory Syncytial Virus Infection | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
